03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Oxford Gene, Baylor deal

Oxford Gene Technology granted Baylor College of Medicine’s Baylor Miraca Genetics Laboratories rights to single nucleotide polymorphism (SNP) array probe technology to identify genetic syndromes. OGT said the technology overcomes limitations and provides a superior...
08:00 , Mar 2, 2015 |  BioCentury  |  Emerging Company Profile

The road to Tau

Asceneuron S.A. is working to treat neurodegeneration by preventing formation of neurofibrillary tangles in the hopes this mechanism will fare better in treating Alzheimer's disease than amyloid-targeted products. Neurofibrillary tangles arise when microtubule-associated protein tau...
08:00 , Feb 6, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Wounds O-linked N-acetylglucosamine (GlcNAc) transferase (OGT) In vitro studies suggest blocking OGT activity could help treat diabetic skin wounds. In human keratinocytes cultured in hyperglycemic...
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Oxford Gene sales and marketing update

OGT launched CytoSure Single Cell Aneuploidy array for pre-implantation genetic screening (PGS) to improve the chances of successful in vitro fertilization (IVF). The array detects aneuploidies across all 24 human chromosomes using DNA amplified from...
07:00 , Apr 9, 2012 |  BC Week In Review  |  Clinical News

Brazaves miglustat regulatory update

Japan's Ministry of Health, Labor and Welfare (MHLW) approved Actelion's Brazaves miglustat to treat Niemann-Pick type C disease. Miglustat is marketed as Zavesca for the indication in 42 countries including Australia, Brazil, Canada, Russia, South...
08:00 , Feb 9, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Prostate cancer O-Linked N-acetylglucosamine transferase (OGT) Mouse studies suggest inhibiting OGT could help treat prostate cancer. In a mouse xenograft model of prostate cancer, small...
07:00 , Oct 11, 2010 |  BC Week In Review  |  Clinical News

Tracleer bosentan regulatory update

FDA issued a warning letter to Actelion after an inspection revealed that the company failed to comply with postmarketing safety reporting requirements for 3 drugs. FDA said the company failed to report serious and unexpected...
07:00 , Mar 29, 2010 |  BC Week In Review  |  Clinical News

Zavesca miglustat regulatory update

Health Canada approved Actelion's Zavesca miglustat to treat Niemann-Pick type C disease. Zavesca is also approved in Australia, Brazil, Russia, South Korea and the EU in the indication. The oral N-butyldeoxynojirimycin glucosyltransferase inhibitor is approved...
07:00 , Mar 15, 2010 |  BC Week In Review  |  Clinical News

Zavesca miglustat regulatory update

FDA issued a complete response letter for an sNDA from Actelion for Zavesca miglustat to treat progressive neurological manifestations in patients with Niemann-Pick type C disease. The agency asked Actelion to provide additional preclinical and...